title: Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.
abstract: BACKGROUND
  Women with hormone-responsive metastatic breast cancer (MBC) may respond to or have stable disease with a number of hormone therapies. We explored the efficacy and safety of the steroidal aromatase inactivator exemestane as first-line hormonal therapy in MBC in postmenopausal women.
  
  
  METHODS
  Patients with measurable disease were eligible if they had received no prior hormone therapy for metastatic disease and had hormone receptor positive disease or hormone receptor unknown disease with a long disease-free interval from adjuvant therapy. They were randomized to tamoxifen 20 mg/day or exemestane 25 mg/day in this open-label study.
  
  
  RESULTS
  Blinded independently reviewed response rates for exemestane and tamoxifen were 41% and 17%, respectively. Fifty-seven per cent of exemestane- and 42% of tamoxifen-treated patients experienced clinical benefit, defined as complete or partial response, or disease stabilization lasting at least 6 months. There was a low incidence of severe flushing, sweating, nausea and edema in women who received exemestane. One exemestane-treated patient had a pulmonary embolism with grade 4 dyspnea.
  
  
  CONCLUSIONS
  Exemestane is well tolerated and active in the first-line treatment of hormone-responsive MBC. An ongoing EORTC phase III trial is comparing the efficacy, measuring time-to-disease progression, of exemestane and tamoxifen.
authors.affiliation: Universitair Ziekenhuis, Gasthuisberg, Leuven, Belgium. robert.paridaes@uz.kuleuven.ac.be
authors.forename: R
authors.initials: R
authors.lastname: Paridaens
authors.forename: L
authors.initials: L
authors.lastname: Dirix
authors.forename: C
authors.initials: C
authors.lastname: Lohrisch
authors.forename: L
authors.initials: L
authors.lastname: Beex
authors.forename: M
authors.initials: M
authors.lastname: Nooij
authors.forename: D
authors.initials: D
authors.lastname: Cameron
authors.forename: L
authors.initials: L
authors.lastname: Biganzoli
authors.forename: T
authors.initials: T
authors.lastname: Cufer
authors.forename: L
authors.initials: L
authors.lastname: Duchateau
authors.forename: A
authors.initials: A
authors.lastname: Hamilton
authors.forename: J P
authors.initials: JP
authors.lastname: Lobelle
authors.forename: M
authors.initials: M
authors.lastname: Piccart
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000730:Androstadienes / Q000009:adverse effects / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D005260:Female; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; C056516:exemestane